| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Inflammatory Agents, Non-Steroidal | 30 | 2021 | 521 | 3.280 |
Why?
|
| Neoplasms | 69 | 2023 | 15193 | 2.910 |
Why?
|
| Colorectal Neoplasms | 43 | 2024 | 3578 | 2.730 |
Why?
|
| Aspirin | 15 | 2021 | 455 | 2.500 |
Why?
|
| Anticarcinogenic Agents | 28 | 2017 | 362 | 2.390 |
Why?
|
| Cyclooxygenase Inhibitors | 20 | 2017 | 177 | 2.270 |
Why?
|
| Health Promotion | 4 | 2024 | 502 | 2.110 |
Why?
|
| Adenoma | 22 | 2018 | 716 | 2.110 |
Why?
|
| Precancerous Conditions | 22 | 2023 | 1058 | 1.610 |
Why?
|
| Chemoprevention | 24 | 2015 | 241 | 1.500 |
Why?
|
| Public Health | 5 | 2023 | 299 | 1.480 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 18 | 2015 | 200 | 1.420 |
Why?
|
| Biomedical Research | 9 | 2018 | 806 | 1.240 |
Why?
|
| Celecoxib | 23 | 2018 | 200 | 1.110 |
Why?
|
| Clinical Trials as Topic | 21 | 2017 | 3719 | 1.060 |
Why?
|
| Early Detection of Cancer | 9 | 2024 | 1258 | 1.040 |
Why?
|
| Adenomatous Polyps | 5 | 2015 | 45 | 0.990 |
Why?
|
| Sulfonamides | 21 | 2012 | 1823 | 0.930 |
Why?
|
| Smoking | 12 | 2022 | 2440 | 0.890 |
Why?
|
| Colonic Polyps | 7 | 2020 | 209 | 0.870 |
Why?
|
| Pyrazoles | 21 | 2012 | 1471 | 0.860 |
Why?
|
| Eflornithine | 7 | 2015 | 59 | 0.830 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2019 | 63 | 0.820 |
Why?
|
| Barrett Esophagus | 9 | 2014 | 569 | 0.800 |
Why?
|
| Primary Prevention | 4 | 2018 | 255 | 0.800 |
Why?
|
| Humans | 186 | 2024 | 261506 | 0.770 |
Why?
|
| Health Behavior | 2 | 2024 | 603 | 0.720 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 284 | 0.690 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 860 | 0.680 |
Why?
|
| Biomarkers, Tumor | 23 | 2022 | 10331 | 0.680 |
Why?
|
| Carcinogens | 4 | 2019 | 384 | 0.670 |
Why?
|
| Colonoscopy | 9 | 2024 | 518 | 0.660 |
Why?
|
| Papillomavirus Vaccines | 2 | 2022 | 195 | 0.640 |
Why?
|
| Health Plan Implementation | 3 | 2020 | 90 | 0.620 |
Why?
|
| Universities | 2 | 2019 | 160 | 0.620 |
Why?
|
| Nicotine | 1 | 2019 | 244 | 0.610 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 849 | 0.600 |
Why?
|
| Isoenzymes | 8 | 2003 | 614 | 0.600 |
Why?
|
| Health Services | 1 | 2018 | 105 | 0.600 |
Why?
|
| Sulindac | 7 | 2020 | 51 | 0.590 |
Why?
|
| Population Health | 1 | 2018 | 51 | 0.590 |
Why?
|
| Aromatase Inhibitors | 2 | 2018 | 305 | 0.580 |
Why?
|
| Blogging | 1 | 2016 | 5 | 0.580 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 600 | 0.570 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 6 | 2023 | 469 | 0.560 |
Why?
|
| Dinoprostone | 3 | 2015 | 208 | 0.550 |
Why?
|
| Esophageal Neoplasms | 10 | 2014 | 3168 | 0.540 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 884 | 0.540 |
Why?
|
| Prostaglandins | 2 | 2018 | 77 | 0.540 |
Why?
|
| Adenomatous Polyposis Coli | 9 | 2010 | 221 | 0.530 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 7789 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 2403 | 0.510 |
Why?
|
| Exercise | 6 | 2024 | 1183 | 0.500 |
Why?
|
| United States | 20 | 2024 | 15433 | 0.500 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2008 | 208 | 0.500 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2014 | 461 | 0.490 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 383 | 0.480 |
Why?
|
| Developing Countries | 1 | 2016 | 315 | 0.470 |
Why?
|
| Nanotechnology | 1 | 2014 | 137 | 0.470 |
Why?
|
| Research Design | 7 | 2015 | 1544 | 0.460 |
Why?
|
| Medical Oncology | 5 | 2019 | 1423 | 0.460 |
Why?
|
| Program Development | 3 | 2008 | 261 | 0.440 |
Why?
|
| Allopurinol | 1 | 2013 | 54 | 0.440 |
Why?
|
| Obesity | 4 | 2023 | 2884 | 0.430 |
Why?
|
| Blood Platelets | 4 | 2018 | 731 | 0.420 |
Why?
|
| SEER Program | 2 | 2014 | 1000 | 0.420 |
Why?
|
| Guideline Adherence | 1 | 2016 | 636 | 0.410 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 10 | 2018 | 215 | 0.410 |
Why?
|
| Minority Groups | 1 | 2014 | 322 | 0.400 |
Why?
|
| Patient Selection | 5 | 2017 | 2055 | 0.390 |
Why?
|
| Diet | 8 | 2024 | 1440 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2021 | 2027 | 0.380 |
Why?
|
| Adult | 48 | 2024 | 77950 | 0.360 |
Why?
|
| Research | 5 | 2019 | 415 | 0.340 |
Why?
|
| Liver Neoplasms | 8 | 2021 | 4557 | 0.340 |
Why?
|
| Colonic Neoplasms | 9 | 2010 | 1390 | 0.330 |
Why?
|
| Cancer Vaccines | 2 | 2011 | 697 | 0.330 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 598 | 0.320 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 761 | 0.310 |
Why?
|
| Female | 74 | 2023 | 141928 | 0.310 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 211 | 0.310 |
Why?
|
| Male | 73 | 2022 | 123000 | 0.310 |
Why?
|
| Cyclooxygenase 2 | 10 | 2017 | 483 | 0.310 |
Why?
|
| Environmental Exposure | 2 | 2020 | 288 | 0.300 |
Why?
|
| Middle Aged | 53 | 2024 | 86204 | 0.300 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 227 | 0.290 |
Why?
|
| Societies, Scientific | 2 | 2018 | 74 | 0.280 |
Why?
|
| Preoperative Care | 1 | 2013 | 1529 | 0.280 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 1299 | 0.280 |
Why?
|
| Antineoplastic Agents | 17 | 2016 | 14289 | 0.280 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 421 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.270 |
Why?
|
| Alopecia | 2 | 2001 | 126 | 0.270 |
Why?
|
| Drugs, Investigational | 2 | 2005 | 135 | 0.270 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2023 | 77 | 0.270 |
Why?
|
| Risk Factors | 23 | 2023 | 17523 | 0.260 |
Why?
|
| Cholagogues and Choleretics | 2 | 2004 | 33 | 0.260 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 941 | 0.260 |
Why?
|
| Ursodeoxycholic Acid | 2 | 2004 | 51 | 0.260 |
Why?
|
| International Cooperation | 3 | 2018 | 323 | 0.260 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 7222 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2008 | 2594 | 0.250 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2019 | 2359 | 0.250 |
Why?
|
| Intestinal Mucosa | 6 | 2023 | 1081 | 0.240 |
Why?
|
| Preventive Medicine | 1 | 2004 | 28 | 0.240 |
Why?
|
| Forecasting | 4 | 2016 | 694 | 0.240 |
Why?
|
| Cyclooxygenase 1 | 5 | 2017 | 67 | 0.240 |
Why?
|
| Risk Assessment | 12 | 2017 | 6869 | 0.240 |
Why?
|
| Carcinogenesis | 3 | 2020 | 1026 | 0.240 |
Why?
|
| Aged | 40 | 2024 | 70117 | 0.230 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2024 | 53 | 0.230 |
Why?
|
| Colon | 6 | 2006 | 670 | 0.230 |
Why?
|
| Congresses as Topic | 2 | 2018 | 298 | 0.230 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 907 | 0.220 |
Why?
|
| Incidence | 8 | 2022 | 5673 | 0.220 |
Why?
|
| Models, Animal | 2 | 2005 | 664 | 0.220 |
Why?
|
| Politics | 1 | 2023 | 74 | 0.220 |
Why?
|
| Neoplasms, Experimental | 4 | 2005 | 750 | 0.220 |
Why?
|
| Animals | 33 | 2020 | 59536 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2022 | 1833 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2013 | 2947 | 0.210 |
Why?
|
| Case-Control Studies | 8 | 2023 | 6100 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2019 | 4549 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2012 | 5539 | 0.210 |
Why?
|
| Societies, Medical | 3 | 2018 | 1335 | 0.200 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 487 | 0.200 |
Why?
|
| Life Style | 3 | 2016 | 612 | 0.200 |
Why?
|
| Membrane Proteins | 9 | 2013 | 2819 | 0.200 |
Why?
|
| Students | 2 | 2021 | 324 | 0.200 |
Why?
|
| Education, Distance | 1 | 2022 | 93 | 0.200 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2020 | 98 | 0.190 |
Why?
|
| Risk | 7 | 2016 | 1972 | 0.190 |
Why?
|
| Mexican Americans | 2 | 2022 | 322 | 0.190 |
Why?
|
| Texas | 7 | 2022 | 6311 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 171 | 0.190 |
Why?
|
| Conserved Sequence | 2 | 2012 | 469 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 1331 | 0.190 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 236 | 0.190 |
Why?
|
| Software Design | 3 | 2008 | 40 | 0.190 |
Why?
|
| Sigmoidoscopy | 2 | 2015 | 47 | 0.190 |
Why?
|
| Cultural Diversity | 2 | 2019 | 76 | 0.180 |
Why?
|
| Hepatitis C Antibodies | 1 | 2020 | 41 | 0.180 |
Why?
|
| Gene Expression Profiling | 7 | 2023 | 5159 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2012 | 4938 | 0.180 |
Why?
|
| Mexico | 2 | 2021 | 259 | 0.180 |
Why?
|
| Placebos | 10 | 2011 | 437 | 0.180 |
Why?
|
| Mass Screening | 4 | 2020 | 1509 | 0.180 |
Why?
|
| Adolescent | 9 | 2024 | 31252 | 0.180 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2019 | 13 | 0.180 |
Why?
|
| Disease Progression | 9 | 2021 | 6682 | 0.180 |
Why?
|
| Pesticides | 1 | 2019 | 25 | 0.180 |
Why?
|
| Organophosphates | 1 | 2019 | 41 | 0.170 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 28 | 0.170 |
Why?
|
| Schools | 1 | 2021 | 233 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 15862 | 0.170 |
Why?
|
| Apoptosis | 6 | 2008 | 7591 | 0.170 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 2265 | 0.170 |
Why?
|
| Vaping | 1 | 2019 | 33 | 0.170 |
Why?
|
| Resistance Training | 1 | 2019 | 42 | 0.170 |
Why?
|
| Serum Albumin, Bovine | 1 | 2019 | 83 | 0.170 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 15694 | 0.170 |
Why?
|
| Cardiovascular Diseases | 9 | 2011 | 2195 | 0.170 |
Why?
|
| Health Communication | 1 | 2019 | 37 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 3 | 2013 | 589 | 0.170 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 483 | 0.170 |
Why?
|
| Diplomacy | 1 | 2018 | 11 | 0.170 |
Why?
|
| Nutrition Surveys | 1 | 2000 | 295 | 0.160 |
Why?
|
| Culture | 1 | 2019 | 100 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 493 | 0.160 |
Why?
|
| Patient Compliance | 2 | 2020 | 667 | 0.160 |
Why?
|
| Smokers | 1 | 2019 | 143 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2011 | 441 | 0.160 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 493 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2024 | 1819 | 0.160 |
Why?
|
| Smoking Prevention | 1 | 2019 | 138 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2021 | 448 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 88 | 0.160 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 333 | 0.160 |
Why?
|
| Selenomethionine | 3 | 2006 | 41 | 0.160 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 268 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2011 | 574 | 0.150 |
Why?
|
| Hepacivirus | 1 | 2020 | 397 | 0.150 |
Why?
|
| Lung | 2 | 2019 | 3151 | 0.150 |
Why?
|
| Young Adult | 9 | 2022 | 21445 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Double-Blind Method | 11 | 2012 | 2588 | 0.140 |
Why?
|
| American Cancer Society | 1 | 2016 | 31 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2016 | 2086 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 499 | 0.140 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 37 | 0.140 |
Why?
|
| Biomarkers | 7 | 2018 | 5047 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 2 | 2016 | 430 | 0.140 |
Why?
|
| Overweight | 1 | 2020 | 484 | 0.140 |
Why?
|
| Bronchi | 3 | 2004 | 326 | 0.140 |
Why?
|
| Trust | 1 | 2017 | 99 | 0.140 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 1341 | 0.140 |
Why?
|
| Smoking Cessation | 2 | 2021 | 712 | 0.140 |
Why?
|
| Eicosanoids | 1 | 2015 | 31 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2018 | 291 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2019 | 465 | 0.130 |
Why?
|
| Drug Design | 4 | 2003 | 375 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 253 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 882 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 748 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2021 | 9244 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.130 |
Why?
|
| Genotype | 8 | 2017 | 4109 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 2508 | 0.120 |
Why?
|
| Proteomics | 1 | 2022 | 1380 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 1209 | 0.120 |
Why?
|
| Mutation | 6 | 2019 | 15179 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2014 | 54 | 0.120 |
Why?
|
| Women | 1 | 2014 | 27 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1225 | 0.120 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 338 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2012 | 2341 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 1547 | 0.120 |
Why?
|
| Gene Expression | 4 | 2006 | 3570 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 980 | 0.120 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 29902 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 5437 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 294 | 0.120 |
Why?
|
| Prostatic Neoplasms | 4 | 2009 | 5767 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 419 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 202 | 0.110 |
Why?
|
| Glucose | 2 | 2018 | 1248 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 291 | 0.110 |
Why?
|
| Lipase | 1 | 2013 | 112 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5687 | 0.110 |
Why?
|
| Intestinal Neoplasms | 2 | 2008 | 189 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 2008 | 418 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 5061 | 0.110 |
Why?
|
| Immune System | 1 | 2014 | 279 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 153 | 0.110 |
Why?
|
| Inflammation | 4 | 2018 | 2522 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2019 | 650 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 167 | 0.110 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2012 | 29 | 0.110 |
Why?
|
| Liposomes | 1 | 2014 | 684 | 0.110 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 17 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 256 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 227 | 0.100 |
Why?
|
| Wound Healing | 1 | 2017 | 815 | 0.100 |
Why?
|
| beta Catenin | 1 | 2016 | 688 | 0.100 |
Why?
|
| Amines | 1 | 2012 | 85 | 0.100 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 14889 | 0.100 |
Why?
|
| Meat | 1 | 2012 | 87 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1362 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 119 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2019 | 1154 | 0.100 |
Why?
|
| Occult Blood | 2 | 2020 | 64 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4314 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 104 | 0.100 |
Why?
|
| Genes, APC | 2 | 2001 | 70 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2013 | 246 | 0.100 |
Why?
|
| Aging | 2 | 2015 | 1582 | 0.100 |
Why?
|
| Enalapril | 1 | 2010 | 20 | 0.090 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 13658 | 0.090 |
Why?
|
| Poverty | 1 | 2014 | 471 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 1283 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2022 | 12873 | 0.090 |
Why?
|
| Mice | 12 | 2020 | 34495 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2000 | 24 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2000 | 82 | 0.090 |
Why?
|
| Esophagus | 3 | 2013 | 553 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2013 | 324 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Lipoxygenase | 2 | 2018 | 24 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 244 | 0.090 |
Why?
|
| Survivors | 1 | 2015 | 1031 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.090 |
Why?
|
| Medicare | 1 | 2014 | 860 | 0.090 |
Why?
|
| Genomics | 2 | 2017 | 2738 | 0.090 |
Why?
|
| Biological Products | 1 | 2013 | 274 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2015 | 2203 | 0.090 |
Why?
|
| Selenium | 1 | 2009 | 47 | 0.090 |
Why?
|
| History, 18th Century | 1 | 2009 | 89 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2016 | 11965 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.080 |
Why?
|
| Proteome | 2 | 2004 | 561 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 78 | 0.080 |
Why?
|
| Vitamin E | 1 | 2009 | 136 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2009 | 154 | 0.080 |
Why?
|
| Transcriptome | 2 | 2018 | 1859 | 0.080 |
Why?
|
| Government Programs | 1 | 2008 | 15 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 10035 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 2315 | 0.080 |
Why?
|
| Government Regulation | 1 | 2008 | 67 | 0.080 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 3 | 2004 | 15 | 0.080 |
Why?
|
| Pravastatin | 1 | 2008 | 34 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 6295 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 58 | 0.080 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 11538 | 0.080 |
Why?
|
| Telemedicine | 1 | 2014 | 471 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2007 | 329 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 527 | 0.080 |
Why?
|
| Simvastatin | 1 | 2008 | 106 | 0.080 |
Why?
|
| Models, Biological | 4 | 2008 | 3254 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2008 | 72 | 0.070 |
Why?
|
| Hyperplasia | 2 | 2019 | 557 | 0.070 |
Why?
|
| Decision Making | 1 | 2014 | 1287 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 4988 | 0.070 |
Why?
|
| Genetic Heterogeneity | 2 | 2019 | 318 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2007 | 1162 | 0.070 |
Why?
|
| Publishing | 1 | 2008 | 220 | 0.070 |
Why?
|
| Global Health | 2 | 2023 | 657 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2013 | 2669 | 0.070 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 575 | 0.070 |
Why?
|
| Rats | 6 | 2012 | 6086 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1375 | 0.060 |
Why?
|
| Treatment Outcome | 11 | 2017 | 32848 | 0.060 |
Why?
|
| Intestinal Polyposis | 1 | 2004 | 30 | 0.060 |
Why?
|
| Budesonide | 1 | 2004 | 34 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 4654 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 2291 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 3472 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2010 | 992 | 0.060 |
Why?
|
| Colon, Descending | 1 | 2003 | 6 | 0.060 |
Why?
|
| Colon, Ascending | 1 | 2003 | 12 | 0.060 |
Why?
|
| Cameroon | 1 | 2022 | 15 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1960 | 0.060 |
Why?
|
| Biology | 1 | 2023 | 75 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 2803 | 0.060 |
Why?
|
| Anethole Trithione | 1 | 2002 | 1 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1085 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2004 | 294 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2004 | 153 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 259 | 0.050 |
Why?
|
| Prognosis | 6 | 2018 | 21713 | 0.050 |
Why?
|
| Azoxymethane | 2 | 1999 | 43 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2004 | 219 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 86 | 0.050 |
Why?
|
| Antioxidants | 3 | 2001 | 507 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2004 | 1313 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 57 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2021 | 24 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2022 | 46 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2002 | 122 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2002 | 56 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 4971 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2008 | 6009 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 519 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 334 | 0.050 |
Why?
|
| Duodenal Neoplasms | 1 | 2002 | 138 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2002 | 123 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2012 | 575 | 0.050 |
Why?
|
| Colombia | 1 | 2021 | 66 | 0.050 |
Why?
|
| Age of Onset | 2 | 2015 | 827 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 974 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2000 | 447 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2019 | 875 | 0.050 |
Why?
|
| Piroxicam | 1 | 2000 | 5 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 165 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 1467 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2001 | 216 | 0.050 |
Why?
|
| Biopsy | 4 | 2017 | 3443 | 0.050 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 133 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 2283 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2002 | 339 | 0.050 |
Why?
|
| Ki-67 Antigen | 4 | 2004 | 666 | 0.050 |
Why?
|
| Attitude | 1 | 2021 | 159 | 0.050 |
Why?
|
| Prevalence | 3 | 2020 | 3260 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 177 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4892 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2004 | 665 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 108 | 0.040 |
Why?
|
| Folic Acid | 1 | 2001 | 349 | 0.040 |
Why?
|
| Allelic Imbalance | 1 | 2019 | 41 | 0.040 |
Why?
|
| DNA Repair | 2 | 2004 | 1872 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 1999 | 122 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2000 | 332 | 0.040 |
Why?
|
| Thromboxane-A Synthase | 1 | 2018 | 22 | 0.040 |
Why?
|
| Capital Financing | 1 | 2018 | 13 | 0.040 |
Why?
|
| Feces | 1 | 2002 | 770 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2019 | 227 | 0.040 |
Why?
|
| Receptors, Prostaglandin | 1 | 2018 | 29 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 543 | 0.040 |
Why?
|
| Health Planning | 1 | 2018 | 26 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 63 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1999 | 79 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 64 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7551 | 0.040 |
Why?
|
| Latin America | 1 | 2018 | 115 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2018 | 75 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2000 | 566 | 0.040 |
Why?
|
| Aromatase | 1 | 1998 | 56 | 0.040 |
Why?
|
| Pyrazines | 1 | 2001 | 495 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 402 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 233 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2019 | 120 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 508 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 671 | 0.040 |
Why?
|
| Cadherins | 2 | 2013 | 660 | 0.040 |
Why?
|
| Counseling | 1 | 2020 | 381 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 518 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.040 |
Why?
|
| Ketoprofen | 1 | 1996 | 2 | 0.040 |
Why?
|
| Mice, Hairless | 1 | 2016 | 55 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 856 | 0.040 |
Why?
|
| Phylogeny | 1 | 2019 | 826 | 0.040 |
Why?
|
| Peptic Ulcer | 2 | 2012 | 140 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 336 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 620 | 0.040 |
Why?
|
| Logistic Models | 2 | 2019 | 3441 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1998 | 342 | 0.030 |
Why?
|
| DNA | 2 | 2002 | 2693 | 0.030 |
Why?
|
| Patient Participation | 1 | 2020 | 446 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 1998 | 333 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2002 | 2316 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 713 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2004 | 1589 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 1244 | 0.030 |
Why?
|
| Mucous Membrane | 2 | 2006 | 271 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 1537 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Paris | 1 | 2014 | 10 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 2488 | 0.030 |
Why?
|
| China | 2 | 2006 | 606 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 575 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1879 | 0.030 |
Why?
|
| Estrogens | 1 | 1998 | 751 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 866 | 0.030 |
Why?
|
| Diclofenac | 1 | 2013 | 11 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 27 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2013 | 64 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4758 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2013 | 56 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 1130 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2001 | 2295 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 3203 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 651 | 0.030 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 134 | 0.030 |
Why?
|
| Taiwan | 1 | 2012 | 93 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 1171 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 14551 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2017 | 785 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1350 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2013 | 217 | 0.030 |
Why?
|
| Cooking | 1 | 2012 | 66 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 249 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 702 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 334 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 237 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3230 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 633 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2003 | 249 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 700 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 1259 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 4821 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5112 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 324 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2005 | 551 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Pharmacokinetics | 2 | 2000 | 42 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 1183 | 0.020 |
Why?
|
| Survival Rate | 2 | 2013 | 12221 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 340 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 409 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1999 | 224 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2013 | 764 | 0.020 |
Why?
|
| Authorship | 1 | 2008 | 53 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 260 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4849 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 515 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 3890 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 4532 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 280 | 0.020 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 44 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2001 | 1544 | 0.020 |
Why?
|
| Sex Factors | 2 | 2004 | 2139 | 0.020 |
Why?
|
| Time Factors | 3 | 2012 | 12926 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2005 | 72 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 9180 | 0.020 |
Why?
|
| Carcinoma | 1 | 2017 | 2578 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2004 | 6942 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 465 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 1144 | 0.020 |
Why?
|
| Tamoxifen | 2 | 1999 | 876 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 78 | 0.010 |
Why?
|
| Pharynx | 1 | 2004 | 153 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1374 | 0.010 |
Why?
|
| Risk Management | 1 | 2004 | 107 | 0.010 |
Why?
|
| Neoplastic Processes | 1 | 2003 | 15 | 0.010 |
Why?
|
| Headache | 1 | 2004 | 163 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2004 | 178 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2004 | 206 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 285 | 0.010 |
Why?
|
| Cough | 1 | 2004 | 116 | 0.010 |
Why?
|
| Environment | 1 | 2004 | 190 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2007 | 6150 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 206 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.010 |
Why?
|
| Cell Division | 2 | 1999 | 2489 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 502 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 16273 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 592 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2054 | 0.010 |
Why?
|
| Drug Approval | 1 | 2003 | 178 | 0.010 |
Why?
|
| Endoscopy | 1 | 2005 | 479 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2003 | 316 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1165 | 0.010 |
Why?
|
| Thiones | 1 | 2001 | 16 | 0.010 |
Why?
|
| Methylation | 1 | 2003 | 597 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 7548 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 691 | 0.010 |
Why?
|
| Metaplasia | 1 | 2002 | 383 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2003 | 731 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2000 | 118 | 0.010 |
Why?
|
| Retinoids | 1 | 2001 | 164 | 0.010 |
Why?
|
| Carotenoids | 1 | 2001 | 96 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10001 | 0.010 |
Why?
|
| Thiophenes | 1 | 2001 | 148 | 0.010 |
Why?
|
| Esophageal Achalasia | 1 | 2000 | 36 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3639 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 259 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2012 | 3518 | 0.010 |
Why?
|
| British Columbia | 1 | 1999 | 24 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 548 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 448 | 0.010 |
Why?
|
| Spirometry | 1 | 1999 | 143 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 2000 | 134 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 634 | 0.010 |
Why?
|
| Fluorescence | 1 | 1999 | 195 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 4638 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1064 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 980 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 118 | 0.010 |
Why?
|
| Antimutagenic Agents | 1 | 1998 | 5 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1013 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1239 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 1493 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 318 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 3569 | 0.010 |
Why?
|
| Computers | 1 | 1998 | 141 | 0.010 |
Why?
|
| Pharmacology, Clinical | 1 | 1997 | 10 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 1439 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1997 | 38 | 0.010 |
Why?
|
| Butylhydroxybutylnitrosamine | 1 | 1996 | 3 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 741 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 1620 | 0.010 |
Why?
|
| Epithelium | 1 | 1999 | 720 | 0.010 |
Why?
|
| Fenretinide | 1 | 1997 | 96 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1996 | 110 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1997 | 184 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1999 | 474 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 2022 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8873 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 482 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 1998 | 1021 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3343 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 3552 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1999 | 1818 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 7226 | 0.010 |
Why?
|
| Prostate | 1 | 1996 | 1088 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 37905 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2000 | 5710 | 0.010 |
Why?
|
| Breast | 1 | 1996 | 1344 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 5317 | 0.010 |
Why?
|
| Pregnancy | 1 | 2000 | 7573 | 0.000 |
Why?
|